What's in UCB Biopharma SRL's pipeline?

UCB Biopharma SRL has 18 drugs in our index: 1 marketed, 0 filed, 5 in Phase 3, 1 in Phase 2, 10 in Phase 1.

Which companies overlap with UCB Biopharma SRL's portfolio?

Top competitors by shared drug class: UCB Pharma, AbbVie (prior sponsor, Abbott), Bausch & Lomb Incorporated, Assaf-Harofeh Medical Center, Azienda Ospedaliera Universitaria Policlinico "G. Martino".

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ucb-biopharma-srl.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

UCB Biopharma SRL — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

UCB Biopharma SRL pipeline: 1 marketed, 0 filed, 5 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 5 Phase 3 1 Phase 2 10 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Brivaracetam oral solution	Brivaracetam oral solution	marketed
brivaracetam (BRV) tablet	brivaracetam (BRV) tablet	phase 3	SV2A receptor agonist	SV2A	Neurology
Staccato alprazolam	Staccato alprazolam	phase 3	Benzodiazepine	GABA-A receptor	Psychiatry / Neurology
Brivaracetam Film-coated tablet	Brivaracetam Film-coated tablet	phase 3	Antiepileptic agent (SV2A ligand)	SV2A (synaptic vesicle protein 2A)	Neurology
zilucoplan (RA101495)	zilucoplan (RA101495)	phase 3	S1P receptor modulator	S1P1	Immunology
DZP	DZP	phase 3	Benzodiazepine	GABA-A receptor	Neurology, Psychiatry

Therapeutic area mix

Neurology · 2
Immunology · 1
Neurology, Psychiatry · 1
Neuroscience · 1
Other · 1
Psychiatry / Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

UCB Pharma · 2 shared drug classes
AbbVie (prior sponsor, Abbott) · 1 shared drug class
Bausch & Lomb Incorporated · 1 shared drug class
Assaf-Harofeh Medical Center · 1 shared drug class
Azienda Ospedaliera Universitaria Policlinico "G. Martino" · 1 shared drug class
B.P. Koirala Institute of Health Sciences · 1 shared drug class
Ajenat Pharms · 1 shared drug class
AO GENERIUM · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for UCB Biopharma SRL:

Cite this brief

Drug Landscape (2026). UCB Biopharma SRL — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ucb-biopharma-srl. Accessed 2026-05-16.